Joe Chang, MD, PhD, MS, FASTRO

Dr. Chang holds a tenured Texas 4000 Distinguished Professorship at MD Anderson Cancer Center. He is an appointed American Society of Radiation Oncology Fellow and has been recognized with the Best Doctors of America award. He is one of the pioneers in the field of stereotactic ablative radiotherapy (SABR) and proton therapy for lung cancer, having published more than 280 peer-reviewed articles in prestigious journals, including LANCET, Nature, JAMA, Journal of Clinical Oncology, Journal of Thoracic Oncology, and various others. His randomized study comparing surgery vs SABR in operable stage I lung cancer, concurrent proton therapy and chemotherapy in stage III lung cancer, and the implementation of intensity-modulated proton therapy (IMPT) in lung cancer was among the first reported clinical studies in the world to do so. His research has helped establish the role of SABR, proton therapy, and combined immunotherapy and SABR (I-SABR) in lung cancer; currently, he is the principle investigator of a randomized study of I-SABR in early stage lung cancer. He is a voting committee member of NCCN thoracic guidelines and chairs both the international proton therapy PTCOG thoracic and American Radium Society Thoracic AUS committees. Additionally, on behalf of national and international societies, Dr. Chang has led several important consensus statements that have significantly impacted in radiation oncology community about SABR, proton therapy in lung cancer, IMPT in moving thoracic cancers, management of small cell lung cancer, oligometastasis, and re-irradiation of thoracic cancer.

Disclosures: